Antagonism of kappa opioid receptors accelerates the development of L-DOPA-induced dyskinesia in a preclinical model of moderate dopamine depletion.


Journal

Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503

Informations de publication

Date de publication:
15 12 2023
Historique:
received: 03 08 2023
revised: 21 09 2023
accepted: 29 09 2023
medline: 6 11 2023
pubmed: 3 10 2023
entrez: 2 10 2023
Statut: ppublish

Résumé

Levels of the opioid peptide dynorphin, an endogenous ligand selective for kappa-opioid receptors (KORs), its mRNA and pro-peptide precursors are differentially dysregulated in Parkinson's disease (PD) and following the development of l-DOPA-induced dyskinesia (LID). It remains unclear whether these alterations contribute to the pathophysiological mechanisms underlying PD motor impairment and the subsequent development of LID, or whether they are part of compensatory mechanisms. We sought to investigate nor-BNI, a KOR antagonist, 1) in the dopamine (DA)-depleted PD state, 2) during the development phase of LID, and 3) via measuring of tonic levels of striatal DA. While nor-BNI (3 mg/kg; s.c.) did not lead to functional restoration in the DA-depleted state, it affected the dose-dependent development of abnormal voluntary movements (AIMs) in response to escalating doses of l-DOPA in a rat PD model with a moderate striatal 6-hydroxdopamine (6-OHDA) lesion. We tested five escalating doses of l-DOPA (6, 12, 24, 48, 72 mg/kg; i.p.), and nor-BNI significantly increased the development of AIMs at the 12 and 24 mg/kg l-DOPA doses. However, after reaching the 72 mg/kg l-DOPA, AIMs were not significantly different between control and nor-BNI groups. In summary, while blocking KORs significantly increased the rate of development of LID induced by chronic, escalating doses of l-DOPA in a moderate-lesioned rat PD model, it did not contribute further once the overall severity of LID was established. While we observed an increase of tonic DA levels in the moderately lesioned dorsolateral striatum, there was no tonic DA change following administration of nor-BNI.

Identifiants

pubmed: 37783263
pii: S0006-8993(23)00384-0
doi: 10.1016/j.brainres.2023.148613
pii:
doi:

Substances chimiques

Levodopa 46627O600J
Dopamine VTD58H1Z2X
Receptors, Opioid, kappa 0
Oxidopamine 8HW4YBZ748

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

148613

Subventions

Organisme : NHLBI NIH HHS
ID : T35 HL007479
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008804
Pays : United States

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Andrew J Flores (AJ)

Department of Neurology, The University of Arizona, Tucson, AZ 85724, USA; Graduate Interdisciplinary Program in Physiological Sciences, The University of Arizona, Tucson, AZ 85724, USA.

Mitchell J Bartlett (MJ)

Department of Neurology, The University of Arizona, Tucson, AZ 85724, USA; Department of Pharmacology, The University of Arizona, Tucson, AZ 85724, USA.

Blake T Seaton (BT)

Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.

Grace Samtani (G)

Department of Neurology, The University of Arizona, Tucson, AZ 85724, USA.

Morgan R Sexauer (MR)

Department of Neurology, The University of Arizona, Tucson, AZ 85724, USA.

Nathan C Weintraub (NC)

Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA; Department of Pharmacology, The University of Arizona, Tucson, AZ 85724, USA.

James R Siegenthaler (JR)

Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.

Dong Lu (D)

Department of Pharmacology, The University of Arizona, Tucson, AZ 85724, USA.

Michael L Heien (ML)

Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA.

Frank Porreca (F)

Department of Pharmacology, The University of Arizona, Tucson, AZ 85724, USA.

Scott J Sherman (SJ)

Department of Neurology, The University of Arizona, Tucson, AZ 85724, USA.

Torsten Falk (T)

Department of Neurology, The University of Arizona, Tucson, AZ 85724, USA; Graduate Interdisciplinary Program in Physiological Sciences, The University of Arizona, Tucson, AZ 85724, USA; Department of Pharmacology, The University of Arizona, Tucson, AZ 85724, USA. Electronic address: tfalk@u.arizona.edu.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH